|
1
|
Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management. Chem Phys Lipids 2022; 243:105177. [PMID: 35122739 DOI: 10.1016/j.chemphyslip.2022.105177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 01/17/2022] [Accepted: 01/31/2022] [Indexed: 12/21/2022]
Abstract
The present study focused on the development and evaluation of nanotechnology-based carrier systems of solid lipid nanoparticles (SLNs) to enhance the permeation and bioavailability of zolmitriptan across blood-brain-barrier (BBB). SLNs are the emerging field of nanotechnology with numerous applications like cosmetics and pharmaceutical research. Zolmitriptan-loaded SLNs were prepared by high-pressure homogenization method for targeted drug delivery to the brain. The SLNs were found to be round in shape with particle size ranging from 110 to 200nm and zeta potential upto -24.83± 3.03mV which indicates good colloidal stability. The maximum entrapment efficiency of zolmitriptan in SLNs was found to be 84.17± 12.24%. The in-vitro drug release and ex-vivo release studies exhibited 95.85±2.44% and 82.06±2.94% drug release, respectively for 24h. In-vivo studies was performed on male Wistar rats wherein the concentration of zolmitriptan was estimated in cerebrospinal fluid by LC-MS method. The selected formulation incorporated with SLNs showed significant enhancement in pharmacokinetic parameters like AUC (37.05± 2.45ng/mL), Cmax (42.08 ± 1.32ng/mL), Tmax (30min), and t1/2 (1.28h). Zolmitriptan-loaded SLNs via intranasal administration offers a novel approach to effectively circumvent first-pass hepatic metabolism than conventional oral route with 4-fold alleviation in permeation and 2-fold improvement in bioavailability. DATA AVAILABILITY: The data used to support the findings of this study are included within the article.
Collapse
|
|
2
|
Rani KC, Parfati N, Aryani NLD, Winantari AN, Fitriani EW, Pradana AT, Nawatila R, Putranti AR, Irine F, Angelica F, Yohanes C, Avanti C. Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol. Pharmaceutics 2021; 13:pharmaceutics13101727. [PMID: 34684021 PMCID: PMC8537485 DOI: 10.3390/pharmaceutics13101727] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/10/2021] [Accepted: 10/14/2021] [Indexed: 11/25/2022] Open
Abstract
The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three different types of film former including HPMC E5 4% (w/v), 5% (w/v), CMC-Na 3% (w/v), 4% (w/v), and Na-alginate 2.5% (w/v), 3% (w/v) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively. A solvent casting method was employed to develop ODF of atenolol. The films formed by HPMC E5 produced a smooth and flexible surface, whereas CMC-Na and Na-alginate produced gritty textured films. Satisfactory results were obtained from several physical parameters such as film thickness, folding endurance, swelling index, and disintegration time. The homogeneity, drug content, and dissolution properties of ODF with HPMC exhibited better characteristics than the other formulas. Formula 1 exhibited the highest drug release compared to the other ODFs. The molecular docking results showed that there was a hydrogen bonding between atenolol and film formers which was also supported by the FTIR spectrum. The findings of this study suggest that HPMC E5 is the most favorable film former for ODF of atenolol.
Collapse
Affiliation(s)
- Karina Citra Rani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Nani Parfati
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Ni Luh Dewi Aryani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Agnes Nuniek Winantari
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Endang Wahyu Fitriani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Aditya Trias Pradana
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Roisah Nawatila
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Astridani Rizky Putranti
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Florencia Irine
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Florentia Angelica
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Cintya Yohanes
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Christina Avanti
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
- Correspondence: ; Tel.: +62-31-298-1000
| |
Collapse
|
|
3
|
Olechno K, Basa A, Winnicka K. "Success Depends on Your Backbone"-About the Use of Polymers as Essential Materials Forming Orodispersible Films. MATERIALS 2021; 14:ma14174872. [PMID: 34500962 PMCID: PMC8432670 DOI: 10.3390/ma14174872] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Revised: 08/20/2021] [Accepted: 08/25/2021] [Indexed: 11/24/2022]
Abstract
Polymers constitute a group of materials having a wide-ranging impact on modern pharmaceutical technology. Polymeric components provide the foundation for the advancement of novel drug delivery platforms, inter alia orodispersible films. Orodispersible films are thin, polymeric scraps intended to dissolve quickly when put on the tongue, allowing them to be easily swallowed without the necessity of drinking water, thus eliminating the risk of choking, which is of great importance in the case of pediatric and geriatric patients. Polymers are essential excipients in designing orodispersible films, as they constitute the backbone of these drug dosage form. The type of polymer is of significant importance in obtaining the formulation of the desired quality. The polymers employed to produce orodispersible films must meet particular requirements due to their oral administration and have to provide adequate surface texture, film thickness, mechanical attributes, tensile and folding strength as well as relevant disintegration time and drug release to obtain the final product characterized by optimal pharmaceutical features. A variety of natural and synthetic polymers currently utilized in manufacturing of orodispersible films might be used alone or in a blend. The goal of the present manuscript was to present a review about polymers utilized in designing oral-dissolving films.
Collapse
Affiliation(s)
- Katarzyna Olechno
- Department of Pharmaceutical Technology, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland
- Correspondence: (K.O.); (K.W.)
| | - Anna Basa
- Department of Physical Chemistry, Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Poland;
| | - Katarzyna Winnicka
- Department of Pharmaceutical Technology, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland
- Correspondence: (K.O.); (K.W.)
| |
Collapse
|
|
4
|
Khan QUA, Siddique MI, Rasool F, Naeem M, Usman M, Zaman M. Development and characterization of orodispersible film containing cefixime trihydrate. Drug Dev Ind Pharm 2020; 46:2070-2080. [PMID: 33112681 DOI: 10.1080/03639045.2020.1843477] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Patients suffering from dysphagia have trouble in swallowing conventional oral dosage forms and there is also risk of choking, which may cause patient noncompliance. This study aimed to develop an orodispersible film (ODF) containing cefixime trihydrate (CFX) to cope with the above-mentioned problems as well as to enhance water solubility and masking the bitter taste of the drug. The freeze-drying and kneading methods were used for the formation of inclusion complexes. The physicochemical evaluation revealed that T7 was the best film for the incorporation of pure drug and inclusion complexes. Films were further characterized for physical and mechanical properties. Drug content, dissolving time of the film and drug release tests were performed. In vivo taste and disintegration time studies were also conducted in healthy human volunteers. FTIR spectra of the individual ingredients and prepared formulations have confirmed the chemical compatibilities of the ingredients. The solubility of CFX was increased by complexation with β-CD and optimized freeze-dried inclusion complex (FD1) was selected for the formation of ODF. C4 was selected as an optimized film for the delivery of CFX as this film has released 95.52% drug at the end of 10 min. Dissolution kinetics of FD1 showed that it followed zero-order kinetics while drug release from films, exhibits first-order kinetics; however, both showed non-Fickian transport. In vivo taste evaluation revealed that taste was masked by inclusion complexation with β-CD. However, selected ingredients and employed methodology enabled to formulate film, capable of delivering taste-masked CFX with improved solubility and better patient compliance.
Collapse
Affiliation(s)
- Qurrat-Ul-Ain Khan
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - Muhammad Irfan Siddique
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - Fatima Rasool
- Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan
| | - Muhammad Naeem
- Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan
| | - Muhammad Usman
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - Muhammad Zaman
- Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
| |
Collapse
|
|
6
|
Pitta SK, Dudhipala N, Narala A, Veerabrahma K. Development of zolmitriptan transfersomes by Box–Behnken design for nasal delivery: in vitro and in vivo evaluation. Drug Dev Ind Pharm 2017; 44:484-492. [DOI: 10.1080/03639045.2017.1402918] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Shravan Kumar Pitta
- Laboratory of Nanotechnology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
| | - Narendar Dudhipala
- Laboratory of Nanotechnology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
| | - Arjun Narala
- Laboratory of Nanotechnology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
| | - Kishan Veerabrahma
- Laboratory of Nanotechnology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
| |
Collapse
|